Skip to content
DXCMDexcom

What Is DXCM Fair Value?

Dexcom (DXCM) fair value estimate using multiple valuation models, updated daily.

As of July 16, 2026, Dexcom (DXCM) has a composite fair value estimate of $68.21 based on four valuation models: DCF (41% weight), Graham Number (29% weight), PEG (29% weight), and DDM (0% weight). The current market price is $72.73, suggesting the stock is fair value by 6.2%.

Data as of July 16, 2026 (today)

Composite Fair Value

Fair Value3 of 4 models

$68.21

vs. current price of $72.73(-6.2%)

Undervalued$68.21Overvalued
$72.73

How Is DXCM Fair Value Calculated?

Four independent models estimate what DXCM is worth. Each uses different inputs and assumptions. The composite blends them by weight.

DXCM Intrinsic Value

Forward-looking models based on future cash flows

DCF (Discounted Cash Flow)

41% weight

Estimates how much cash the company will generate over the next 10 years, then calculates what all that future cash is worth in today's dollars. Includes a 15% safety cushion. Try the standalone DCF calculator →

$94.38

+29.8%

Undervalued

Inputs used

FCF: 1.1BGrowth: 21.4%Discount: 12%

DDM (Dividend Discount Model)

0% weight

If a company pays you dividends, this model asks: how much are all those future dividend payments worth today? Only works for stocks that pay dividends. Try the intrinsic value calculator →

N/A

This stock does not pay a dividend, so the DDM cannot be applied. The composite adjusts by redistributing this weight to the other models.

DXCM Fair Value

Current fundamentals: earnings, assets, and growth rate

Graham Number (Value Investing)

29% weight

Created by legendary investor Benjamin Graham. It looks at two things: how much the company earns (EPS) and what its assets are worth (Book Value), then calculates the maximum price a careful investor should pay. Try the fair value calculator →

$21.13

-71.0%

Overvalued

Inputs used

EPS: $2.59Book Value: $7.66

PEG (Price/Earnings to Growth)

29% weight

Checks if you're paying a fair price for the company's growth. A fast-growing company deserves a higher price than a slow one. This model finds the right price based on how fast earnings are growing.

$55.33

-23.9%

Overvalued

Inputs used

EPS: $2.59Growth: 21.4%

What If You Change the Assumptions?

Drag the sliders to test different scenarios. Tap the ? buttons to learn what each input means.

Your DCF Fair Value

$94.38Undervalued

Current price $72.73 is 29.8% below this estimate

CheapFair ValueExpensive
21.4%
0.0%30.0%
12.1%
6.0%15.0%
2.5%
1.0%4.0%
15.0%
0.0%50.0%
View 10-year cash flow projections
YearProjected FCF (Free Cash Flow)Present Value
Year 1$1.28B$1.14B
Year 2$1.56B$1.24B
Year 3$1.89B$1.34B
Year 4$2.29B$1.45B
Year 5$2.78B$1.57B
Year 6$3.38B$1.70B
Year 7$4.10B$1.84B
Year 8$4.98B$2.00B
Year 9$6.04B$2.16B
Year 10$7.33B$2.34B
Terminal Value$78.33B$25.02B

What Are DXCM's Key Financial Metrics?

Earnings & Growth

Current Price

$72.73

EPS (TTM)

$2.28

Forward P/E

23.6

Profit Margin

19.3%

Cash & Balance Sheet

Free Cash Flow

1.1B

EBITDA

1.3B

Book Value

$7.66

Total Debt

1.4B

What Do Analysts Say About DXCM?

Low

$65.00

Average

$85.46

High

$112.00

Upside

+17.5%

Current $72.73Avg Target $85.46Strong Buy24 analysts

DXCM Fair Value FAQ

What is the fair value of DXCM?

Based on our composite model (DCF 35%, Graham 25%, PEG 25%, DDM 15%), DXCM's estimated fair value is $68.21. The stock is currently trading at $72.73, which makes it fair value by our analysis.

How is DXCM's fair value calculated?

We use four valuation methods: Discounted Cash Flow (DCF), Graham Number, PEG-based Fair Value, and Dividend Discount Model (for dividend-paying stocks). The composite score weights DCF at 35%, Graham and PEG at 25% each, and DDM at 15%. When a model can't be applied, its weight is redistributed proportionally.

Is DXCM overvalued or undervalued?

Based on our analysis, DXCM is fair value. The current price of $72.73 is 6.2% above our estimated fair value of $68.21.

What do Wall Street analysts say about DXCM?

24 analysts cover Dexcom with a consensus rating of "Strong Buy." The average price target is $85.46, ranging from $65.00 to $112.00. This implies 17.5% upside from the current price.